Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

AOM , AVMA , CLSM , ISPLF
Sort by: Date|Relevance

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. In an Oct. 25 research note, H.C. Wainwright & Co. analyst Yi Chen reported that newly compiled data support the clinical utility of Interpace Diagnostics Group Inc.'s (IDXG:NA...
Streetwise Reports | October 30, 2019 |

Massive Price Reversion May Be Days or Weeks Away

Our researcher team believes a massive global market price reversion/correction may be setting up and may only be a few days or weeks away from initiating. Our team of dedicated researchers and market analysts have been studying the markets, precious metals, and most recently ...
Chris Vermeulen | September 23, 2019 |

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. Specialty pharmaceutical company Baudax Bio Inc. (BXRX:N...
Streetwise Reports | February 24, 2020 |

Analysis Shows Aug/Sept Market Top Pattern Should Form

We have been pouring over the data and currently believe our earlier prediction of a July/August 2019 market top should be revised to an Aug/Sept 2019 expected market top pattern. The following research posts we authored recently suggested a top may form in July/Aug 2019 and b...
Chris Vermeulen | June 12, 2019 |

Markets Rally Hard - Is The Volatility Move Over?

Many traders are watching the recent 3-day rally thinking “this is the end of the downside price move” and targeting new entry positions for the eventual upside price breakout. We're here to warn you that our ADL predictive modeling system is suggesting w...
Chris Vermeulen | May 17, 2019 |

Stock Market & Flu Breakdown Metrics – Where’s The Bottom?

The end of February was brutal for traders that were not prepared for the breakdown in the US stock markets. The breakdown in price actually started on February 20th and 21st. Most traders didn’t pay attention to these minor downside price rotations in the Te...
Chris Vermeulen | March 3, 2020 |

US Stock Market Sets Up Technical Patterns – Pay Attention

The recent “melt-up” in the US stock market after a moderate downside price move in early May 2020 has set up a number of technical patterns that traders need to pay attention to. This melt-up trend may continue for a bit longer, but price levels and ac...
Chris Vermeulen | June 3, 2020 |

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

This California company expects results from clinical trials in liver disease and psoriasis in 2019. In a March 8 research note, H.C. Wainwright & Co. analyst Ed Arce reported that DURECT Corp. (DRRX:NASDAQ) continues advancing clinical trials evaluating its lead prod...
Streetwise Reports | March 14, 2019 |

Downside Price Rotation Dominates After Manufacturing Data

Our research team has been all over this longer-term Pennant/Flag setup and the potential for the breakdown in the US/Global markets. The US manufacturing data released today confirmed what we believed would be the outcome of the extended trade issues between the US and China ...
Chris Vermeulen | October 2, 2019 |
1 2 3 4 5 6 7 8 9 10 ...